OncoCyte Corporation (OCX)

2,4800 +0,0400 (+1,64%) Alla chiusura: 04:00PM EDT

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600
https://www.oncocyte.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 43

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Joshua Riggs	President, CEO & Director	373,2k	N/D	1983
Mr. James Liu	Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer	192,48k	N/D	1996
Dr. Ekkehard Schutz M.D., Ph.D.	Chief Science Officer	N/D	N/D	N/D
Mr. Peter Hong	VP, General Counsel & Secretary	N/D	N/D	N/D
Mr. Yuh-Min Chiang Ph.D.	Senior Vice President of R&D and Product Development	N/D	N/D	N/D
Ms. Sandra O'Donald	Senior Vice President of Business Operations	N/D	N/D	N/D
Dr. Michael D. West Ph.D.	Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.	N/D	N/D	1953
Ms. Sara Riordan	Director of Medical Education	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Governance aziendale

L'ISS Governance QualityScore di OncoCyte Corporation al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.